Study on the Mechanism of Positive Regulation of YAP by CD166 in Promoting Occurrence and Development of Liver Cancer
DOI:
https://doi.org/10.54097/jwwagq26Keywords:
CD166, Liver Cancer, Cell Proliferation, Apoptosis, Molecular TargetAbstract
This study aims to investigate the role and molecular mechanism of the cell surface molecule CD166 in the occurrence and development of liver cancer. As a malignant tumor with high incidence and mortality, early diagnosis and treatment of liver cancer are of great significance. CD166, known as ALCAM, belongs to the immunoglobulin superfamily, which is intertwined with the ability of tumor cells to proliferate, migrate, and invade. In this study, the expression difference of CD166 in HCC tissues and adjacent normal tissues was analyzed by immunohistochemistry and Western Blot technology. It was found that the expression of CD166 in HCC tissues was significantly upregulated. In further experiments, CD166 in HCC cells was knocked down by RNA interference technology. It was also observed that cell proliferation was inhibited and apoptosis increased, which indicates that CD166 plays a vital role in regulating the growth and survival of HCC cells. The results provide a scientific basis for CD166 as a potential molecular target for early diagnosis and treatment of liver cancer, which is beneficial to promoting liver cancer treatment.
Downloads
References
[1] Li, Xin., Ramadori, Pierluigi., Pfister, Dominik., Seehawer, Marco., & Seehawer, Marco. (2021). The immunological and metabolic landscape in primary and metastatic liver cancer. Nature reviews. Cancer, 21 (9).
[2] Gravitz, Lauren. Liver cancer. Nature, 2014, 516 (7529): S1. Chang, Mei-Hwei.
[3] Hepatitis B virus infection. Seminars in fetal & neonatal medicine, 2007, 12 (3): 160-7.
[4] Weidle UH, Eggle D, Klostermann S, Swart GW. ALCAM/CD166: cancer-related issues. Cancer Genomics Proteomics. 2010 Sep-Oct; 7(5):231-43. PMID: 20952758.
[5] Pinto, Mafalda., Carmo, Alexandre M.. CD6 as a therapeutic target in autoimmune diseases: successes and challenges. BioDrugs: clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2013, 27 (3).
[6] Bowen MA, Aruffo AA, Bajorath J. Cell surface receptors and their ligands: in vitro analysis of CD6-CD166 interactions. Proteins. 2000 Aug 15; 40(3):420-8. PMID: 10861932.
[7] Skonier JE, Bowen MA, Emswiler J, Aruffo A, Bajorath J. Recognition of diverse proteins by members of the immunoglobulin superfamily: delineation of the receiver binding site in the human CD6 ligand ALCAM. Biochemistry. 1996 Sep 24; 35(38):12287-91. doi: 10.1021/bi961038k. PMID: 8823162.
[8] Bowen MA, Bajorath J, D 'Egidio M, Whitney GS, Palmer D, Kobarg J, Starling GC, Siadak AW, Aruffo A. Characterization of mouse ALCAM (CD166): the CD6-binding domain is conserved in different homologs and mediates cross-species binding. Eur J Immunol. 1997 Jun; 27(6):1469-78. doi: 10. 1002/ eji.1830270625. PMID: 9209500.
[9] Ferragut F, Vachetta VS, Troncoso MF, Rabinovich GA, Elola MT. ALCAM/CD166: A pleiotropic mediator of cell adhesion, stemness and cancer progression. Cytokine Growth Factor Rev. 2021 Oct; 61:27-37. doi: 10.1016/j.cytogfr.2021. 07.001. Epub 2021 Jul 9. PMID: 34272152.
[10] Darvishi B, Boroumandieh S, Majidzadeh-A K, Salehi M, Jafari F, Farahmand L. The role of activated leukocyte cell adhesion molecule (ALCAM) in cancer progression, invasion, metastasis and recurrence: A novel cancer stem cell marker and tumor-specific prognostic marker. Exp Mol Pathol. 2020 Aug; 115:104443. doi: 10.1016/j.yexmp.2020. 104443. Epub 2020 May 5. PMID: 32380056.
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

